A Cure for Mantle Cell Lymphoma?

Mantle cell lymphoma (MCL), a rare disease that has been difficult to study in clinical trials, may be curable in the not-so-distant future, according to researchers from the University of Texas.

Studies conducted over the last couple of decades have provided new clues about MCL, enabling doctors and scientists to better understand the disease.

According to Dr. Michael L. Wang, professor in the Department of of Lymphoma/Myeloma at UT's MD Anderson Cancer Center in Houston, the cure may specifically have to do with the patient's age and the initial approach to treatment.

"We are within reach of curing mantle cell lymphoma within a shorter period of time, much sooner than we expected," Dr. Wang told Medscape.

Two intensive therapies

For young and fit patients, the two most effective treatments for MCL have been those that include high-dose cytarabine (HDAC) combined with chemotherapy and autologous stem cell transplantation (ASCT).

"These two intensive therapies have produced overall survival exceeding 10 years. Such overall survival has not been achieved by salvage therapies, such as R-CHOP or bendamustine," Wang said.

Young and healthy patients, Wang explained, can benefit most from primary or frontline therapies used to treat MCL.

"If you mess up with the frontline therapy, you have missed the chance for long-term remission. If you give young, fit patients salvage therapy, their disease will relapse quickly, they will get into a pattern of constant therapies, and they will die from their disease much sooner than 10 years," he said.

Wang's research found that, with proper treatment, younger MCL patients can have a higher survival rate and better quality of life.

"[MCL] used to have a median survival of 3 to 5 years," he said.

Source: Medscape
Image courtesy of Photokanok/FreeDigitalPhotos.net

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap